ES2195998T3 - Sistemas de expresion de dna basados en alfavirus. - Google Patents

Sistemas de expresion de dna basados en alfavirus.

Info

Publication number
ES2195998T3
ES2195998T3 ES92900560T ES92900560T ES2195998T3 ES 2195998 T3 ES2195998 T3 ES 2195998T3 ES 92900560 T ES92900560 T ES 92900560T ES 92900560 T ES92900560 T ES 92900560T ES 2195998 T3 ES2195998 T3 ES 2195998T3
Authority
ES
Spain
Prior art keywords
protein
production
alfavirus
transfection
expression systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900560T
Other languages
English (en)
Inventor
Henrik Garoff
Peter Liljestrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioption AB
Original Assignee
Bioption AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20381182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2195998(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption AB filed Critical Bioption AB
Application granted granted Critical
Publication of ES2195998T3 publication Critical patent/ES2195998T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE HA OBSTACULIZADO LA PRODUCCION DE UNA PROTEINA EFICAZ DE ADN CLONADO EN CELULAS ANIMALES MEDIANTE LA CARENCIA DE SISTEMAS DE EXPRESION ADECUADOS. LOS REQUERIMIENTOS DE DICHO SISTEMA DE EXPRESION SON (1) PRODUCIR FORMAS FUNCIONALES O INMUNOGENICAS DE MOLECULAS DE PROTEINA EN UNA AMPLIA VARIEDAD DE CELULAS ANIMALES, (2) ALTA EFICACIA Y (3) SIMPLICIDAD TECNICA. LA PRESENTE INVENCION SE REFIERE A UNA SOLUCION TECNICA A ESTE PROBLEMA. UNA MOLECULA DE ADN QUE DECODIFICA SECUENCIAS DE PROTEINA ES INSERTADA EN VARIANTES DISEÑADAS DEL CADN DE UN GENOMA DE VIRUS DE ARN POSITIVO ABANDONADO DE UN ALFAVIRUS QUE, A CONTINUACION, A TRAVES DE UNA TRANSCRIPCION Y TRANSFECCION DEL ARN EN CELULAS DE CULTIVO DE TEJIDO, SE UTILIZA PARA PRODUCIR PARTICULAS DE VIRUS QUIMERICOS PARA INMUNIZACION O UN VIRUS RECOMBINANTE PARA LA PRODUCCION DE PROTEINAS. A CAUSA DE LAS CONDICIONES OPTIMIZADAS DE TRANSFECCION Y LA NATURALEZA DE LA REPLICA DEL VIRUS DEL PRESENTE SISTEMA COMBINAN TANTO LA SENCILLEZ COMO LA SEGURIDADEN TERMINOS DE MANEJO, LA EFICACIA EN TERMINOS DE NIVEL DE PRODUCCION DE PROTEINA Y ARN, ASI COMO UN AMPLIO RANGO DE HUESPED.
ES92900560T 1990-12-13 1991-12-12 Sistemas de expresion de dna basados en alfavirus. Expired - Lifetime ES2195998T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon

Publications (1)

Publication Number Publication Date
ES2195998T3 true ES2195998T3 (es) 2003-12-16

Family

ID=20381182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900560T Expired - Lifetime ES2195998T3 (es) 1990-12-13 1991-12-12 Sistemas de expresion de dna basados en alfavirus.

Country Status (12)

Country Link
US (3) US5739026A (es)
EP (1) EP0561890B1 (es)
JP (2) JP3435511B2 (es)
AT (1) ATE236261T1 (es)
AU (1) AU656545B2 (es)
CA (2) CA2614365A1 (es)
DE (1) DE69133228T2 (es)
DK (1) DK0561890T3 (es)
ES (1) ES2195998T3 (es)
FI (1) FI932678A7 (es)
SE (1) SE9003978D0 (es)
WO (1) WO1992010578A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112541A3 (es) * 2004-05-20 2006-03-23 Proyecto Biomedicina Cima Sl Un vector híbrido adenovirus-alfavirus para la administración eficaz y expresión de genes terapéuticos en células tumorales

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
WO1998013511A1 (en) * 1996-09-25 1998-04-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
AU729690B2 (en) * 1996-10-10 2001-02-08 Henrik Garoff Alphavirus-retrovirus vectors
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
CA2306443A1 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
AU749345B2 (en) 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
CA2327835C (en) 1998-04-08 2010-09-21 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
JP4323720B2 (ja) * 1998-05-08 2009-09-02 インターベツト・インターナシヨナル・ベー・ベー 魚膵臓病ウイルス構造タンパク質およびその使用
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
DK1141331T3 (da) 1998-12-16 2009-01-05 Novartis Vaccines & Diagnostic Human cyclinafhængig kinase (hPNQALRE)
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2373300C (en) 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6297013B1 (en) 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
JP2003512077A (ja) * 1999-10-26 2003-04-02 インターナショナル エイズ バクシーン イニシアティブ アルファウイルスレプリコンを発現する侵襲性細菌
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002020721A2 (en) * 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
EP2105496B1 (en) 2000-12-08 2013-02-20 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
CA2479118A1 (en) 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
ATE489969T1 (de) * 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ537003A (en) * 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
BR0312792A (pt) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
AU2003284239B2 (en) 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
AU2003297041B2 (en) 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
AU2003297039B2 (en) * 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004102198A2 (en) * 2003-05-15 2004-11-25 Cytos Biotechnology Ag Selection of b cells with specificity of interest: method of preparation and use
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
EP1706152A2 (en) * 2004-01-20 2006-10-04 Cytos Biotechnology AG Particle-induced ghrelin immune response
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도
US7189540B2 (en) * 2004-06-21 2007-03-13 Quattromed As Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proteins
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
EP1856250B1 (en) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EE05711B1 (et) 2009-10-07 2014-04-15 Tartu Ülikool Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2698635A3 (en) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
EP2668201A2 (en) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunological compositions comprising hiv gp41 polypeptide derivatives
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US20190282679A1 (en) * 2016-04-18 2019-09-19 Rima McLeod Toxoplasma gondii vaccines and their use
IL268856B2 (en) 2017-02-27 2024-09-01 Translate Bio Inc Methods for purification of messenger rna
EP4010481A4 (en) 2019-08-09 2023-09-20 Nutcracker Therapeutics, Inc. MICROFLUIDIC DEVICE AND METHODS OF USE
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288073C (en) * 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112541A3 (es) * 2004-05-20 2006-03-23 Proyecto Biomedicina Cima Sl Un vector híbrido adenovirus-alfavirus para la administración eficaz y expresión de genes terapéuticos en células tumorales
ES2292271A1 (es) * 2004-05-20 2008-03-01 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.

Also Published As

Publication number Publication date
JP4018479B2 (ja) 2007-12-05
AU9078791A (en) 1992-07-08
ATE236261T1 (de) 2003-04-15
US20020151067A1 (en) 2002-10-17
FI932678L (fi) 1993-07-27
US5739026A (en) 1998-04-14
CA2614365A1 (en) 1992-06-25
EP0561890A1 (en) 1993-09-29
JPH06504198A (ja) 1994-05-19
DE69133228T2 (de) 2003-10-30
US6190666B1 (en) 2001-02-20
DK0561890T3 (da) 2003-07-21
DE69133228D1 (de) 2003-05-08
JP2003159085A (ja) 2003-06-03
SE9003978D0 (sv) 1990-12-13
JP3435511B2 (ja) 2003-08-11
AU656545B2 (en) 1995-02-09
FI932678A0 (fi) 1993-06-11
CA2098292A1 (en) 1992-06-14
FI932678A7 (fi) 1993-07-27
EP0561890B1 (en) 2003-04-02
WO1992010578A1 (en) 1992-06-25

Similar Documents

Publication Publication Date Title
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ATE110412T1 (de) Translation von mrna.
CA3146883A1 (en) Modified circular rnas and methods of use thereof
ATE417927T1 (de) Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
CY1118963T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
ES2038579T1 (es) Una celula de levadura del genero schwanniovices.
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
DE69634043D1 (de) Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
KR960010864A (ko) 동물 세포의 형질 감염을 위한 재조합 dna 바이러스 벡터
CO5590973A2 (es) Acido nucleico de adenovirus de simio y secuiencias de aminoacidos, vectores que contienen los mismos y metodos de uso
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
PE38597A1 (es) Nuevo gen derivado de la bacteria coryneforme y uso del mismo
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
ES2062993T3 (es) Factor de crecimiento humano i semejante a la preproinsulina.
CY1106041T1 (el) Καινοφανης συλλεκτινη
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
AR029168A1 (es) Una composicion acidos nucleicos peptidicos y un metodo para prepararla
ES8504248A1 (es) Procedimiento para la fabricacion de un plasmido recombinante que contiene un aminoacido